Neuren Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
Neuren Pharmaceuticals Stock Forecast and Price Target
If the average 2024 price target of $26.58 recently set by four prominent experts for Neuren Pharmaceuticals is met, there would be a potential upside of approximately 38.08% from the last closing price in April, 2024. The high estimate is $31.00, and the low is $22.80. If you're interested in NEU stock, looking at its competitors might also be a good idea.
38.08% Upside
Neuren Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
Neuren Pharmaceuticals's Price has seen growth In the last four years, going from $0.00 to $0.00 – a gain of 100.00% In the next year, analysts believe that Fair Value will reach $20.45 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
12
|
$275.00 | Buy/Sell | $205.51 | -26.12% |
| TLX Stock Forecast | Telix Pharmaceuticals | Buy |
6
|
$15.51 | Buy/Sell | $13.37 | -6.51% |
| PNV Stock Forecast | PolyNovo | Outperform |
8
|
$2.05 | Buy/Sell | $1.88 | 4.39% |
| IMU Stock Forecast | Imugene | Buy |
4
|
$0.08 | Buy/Sell | $0.35 | 425.00% |
| CUV Stock Forecast | Clinuvel Pharmaceuticals | Buy |
16
|
$15.32 | Buy/Sell | $27.41 | 45.23% |
Neuren Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
Neuren Pharmaceuticals's Revenue has seen growth In the last three years, going from $720.00k to $231.94M – a gain of 32113.89% In the following year, 2 experts forecast Neuren Pharmaceuticals's Revenue will decrease by 50.98%, to $113.70M. In 2030, professionals predict that Neuren Pharmaceuticals's Revenue will decrease by 22.98%, to $178.65M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OPT Stock Forecast | Opthea | Underperform |
10
|
$0.64 | Buy/Sell | $1.15 | -45.31% |
| IMM Stock Forecast | Immutep | Buy |
8
|
$0.45 | Buy/Sell | $1.26 | 122.22% |
| MSB Stock Forecast | Mesoblast | Buy |
9
|
$1.09 | Buy/Sell | $0.69 | 0.92% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PYC Stock Forecast | PYC Therapeutics | Buy |
8
|
$0.09 | Buy/Sell | $0.30 | 288.89% |
| CGS Stock Forecast | Cogstate | Buy |
11
|
$1.40 | Buy/Sell | $1.85 | 28.57% |
| BOT Stock Forecast | Botanix Pharmaceuticals | - |
0
|
$0.19 | Buy/Sell | $0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DXB Stock Forecast | Dimerix |
0
|
$0.34 | Buy/Sell | $0.00 | 70.59% | |
| ACW Stock Forecast | Actinogen Medical |
5
|
$0.03 | Buy/Sell | $0.15 | -100.00% | |
| BIT Stock Forecast | Biotron | - |
0
|
$0.06 | Buy/Sell | $0.00 | -100.00% |
Neuren Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Neuren Pharmaceuticals's EBITDA has increased by 2364.32%, going from $-8.80M to $199.26M. According to 3 analysts, Neuren Pharmaceuticals's EBITDA will fall by 49.50% in the next year, reaching $100.63M. The Neuren Pharmaceuticals forecast is for EBITDA to reach $331.21M or grow by 66.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SPL Stock Forecast | Starpharma Holdings | - |
8
|
$0.14 | Buy/Sell | $0.95 | -100.00% |
| IVX Stock Forecast | Invion | - |
0
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| PTX Stock Forecast | Prescient Therapeutics |
2
|
$0.05 | Buy/Sell | $0.20 | 180.00% |
Neuren Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Neuren Pharmaceuticals's EBIT has grown, increasing from $-8.81M to $199.25M – an increase of 2361.63%. In the following year, 4 experts forecast that Neuren Pharmaceuticals's EBIT will decrease by 54.84%, to $89.99M. Over the next seven years, the pros' prediction is EBITof $327.21M, which would mean a seven-year growth forecast of 64.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CYP Stock Forecast | Cynata Therapeutics |
0
|
$0.21 | Buy/Sell | $1.24 | 490.48% | |
| 1AI Stock Forecast | Algorae Pharmaceuticals | - |
-4
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| IMC Stock Forecast | Immuron | - |
0
|
$0.07 | Buy/Sell | $0.00 | -100.00% |
Neuren Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
Neuren Pharmaceuticals's EPS has seen growth In the last four years, going from $-0.09 to $0.00 – a gain of 100.00% In the next year, analysts believe that EPS will reach $0.54 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ATH Stock Forecast | Alterity Therapeutics | - |
0
|
$0.00 | Buy/Sell | $0.75 | 0.00% |
| GTG Stock Forecast | Genetic Technologies | - |
0
|
$0.12 | Buy/Sell | $1.00 | -100.00% |
| OSL Stock Forecast | OncoSil Medical | - |
0
|
$0.01 | Buy/Sell | $0.11 | -100.00% |
Site Navigation
.jpg)